Idiopathic Pulmonary Fibrosis Treatment Market - Top Companies and Manufacturers

Companies Dominating the Idiopathic Pulmonary Fibrosis Treatment Landscape

The companies participating in the idiopathic pulmonary fibrosis treatment market are expanding through R&D investments in new therapies, partnerships to accelerate drug discovery, and acquisitions to enhance their treatment portfolios. Many firms are also focusing on geographic expansion, particularly in emerging markets, to increase accessibility. Regulatory engagement, such as securing orphan drug status, is a key strategy to streamline approvals, while digital patient tools for patient monitoring are becoming integral to improving treatment adherence and personalized care. In September 2024, Boehringer Ingelheim released a statement that its study of nerandomilast, FIBRONEER-IPF, effectively met its primary endpoint, encouraging plans for a new drug request for IPF treatment.

Boehringer Ingelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Bumrungrad International Hospital
Cedars-Sinai
Cleveland Clinic
Bristol-Myers Squibb Company
Cipla Inc.
FibroGen, Inc.
Galapagos NV
Liminal BioSciences Inc.
MediciNova, Inc.
Novartis AG
United Therapeutics

Browse Key Market Insights with Data Illustration:

Idiopathic Pulmonary Fibrosis Treatment Market Size Report 2037

In the News

In August 2024, Reviva Pharmaceuticals Holdings, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent 12053477 covering the use of brilaroxazine for the treatment of IPF.
In December 2023, Boehringer Ingelheim launched Nintedanib, an antifibrotic medication for the treatment of IPF, in Algeria. Additionally, it is the only IPF treatment approved by the Ministry of Health of Algeria.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the idiopathic pulmonary fibrosis treatment market was over USD 3.5 billion.

The market size for the idiopathic pulmonary fibrosis treatment market is projected to reach USD 7.9 billion by the end of 2037 expanding at a CAGR of 7.1% during the forecast period i.e., between 2025-2037.

The major players in the market are Cipla Inc., FibroGen, Inc., Galapagos NV, Liminal BioSciences Inc., and others.

In terms of end use segment, the hospitals & clinic segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 48.1% by the end of 2037 and provide more business opportunities in the future.

Idiopathic Pulmonary Fibrosis Treatment Market - Top Companies and Manufacturers

Companies Dominating the Idiopathic Pulmonary Fibrosis Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the idiopathic pulmonary fibrosis treatment market?

What is the outlook for the idiopathic pulmonary fibrosis treatment market?

Who are the major players dominating the idiopathic pulmonary fibrosis treatment market?

Which end use segment will capture the significant market share for the idiopathic pulmonary fibrosis treatment market by 2037?

Which region will provide more business opportunities for the growth of the idiopathic pulmonary fibrosis treatment market in the future?